Ürolojide botulinum nörotoksin kullanımı

Abstract

Botulinum nörotoksin BoNT çeşitli ürolojik ve ürolojik olmayan hastalıkların tedavisinde, her geçen gün artan bir sıklıkla kullanılmaktadır. Üroloji alanındaki bilgilerin büyük bölümü onabotulinumtoksin A’nın Botox® mesane / detrüsör aşırı aktivitesi DAA , detrüsör-sfinkter dissinerjisi A Botox® into the urethra, prostate, bladder and DSD , benign prostat hiperplazisi BPH , intersipelvic floor for the treatment of voiding and sexual siyel sistit İS / ağrılı mesane sendromu AMS , kronik pelvik ağrı sendromu KPAS ve prematür ejakulasyon PE gibi işeme ve cinsel fonksiyon bozuklukları tedavisinde; üretra, prostat, mesane ve pelvik tabana enjekte edilmesiyle elde edilmiştir.Yapılan çalışmalar BoNT’un dikkatli bir şekilde uygulandığında yüksek etkinlik sağladığını ve düşük yan etki profili ile hastalar tarafından iyi tolere edilebildiğini göstermektedir. Ancak verse event profile. However, multi-center studies BoNT’un uzun dönem etkinlik ve yan etki özellikwith longer follow-up period are required for elulerinin daha iyi değerlendirilebilmesi için çok merkezli ve uzun takip süreli çalışmalara ihtiyaç vardır

Keywords

• Benign prostat hiperplazisi,Botulinum nörotoksin,Detrüsör aşırı aktivitesi,Detrüsör-sfinkter dissinerjisi,İntersisiyel sistit,İşeme fonksiyon bozuklukları,Kronik pelvik ağrı

Botulinum neurotoxin use in urology

Abstract

Botulinum neurotoxin BoNT is increasingly being used for treating various urological and non-urological disorders. Most of our knowledge regarding its use for urological conditions is gathered from the injection of onabotulinumtoxin A Botox® into the urethra, prostate, bladder and pelvic floor for the treatment of voiding and sexual dysfunctions such as bladder / detrusor overactivity, detrusor – sphincter dyssynergia, benign prostatic hyperplasia, interstitial cystitis / painful bladder syndrome, chronic pelvic pain and premature ejaculation. Numerous clinical trials demonstrated that carefully performed BoNT injections are well tolerated because of their high efficacy and low adverse event profile. However, multi-center studies with longer follow-up period are required for elucidating the long-term efficacy and side effects of BoNT therapy

Keywords

• Benign prostatic hyperplasia,Botulinum neurotoxin,Detrusor overactivity,Detrusor – sphincter dyssynergia,Interstitial cystitis,Voiding dysfunction,Chronic pelvic pain

References

1. Van Ermengem E: Ueber einen neuen anaeroben Bacil- lus un seine Beziehungen zum Botulismus. Zeitschrift für Hygiene und Infektionskrankheiten 26:1-56, 1897; transla- tion reprinted in Rev Infect Dis 1979; 1: 701-9.
2. Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health manage- ment. JAMA 2011;285:1059-70.
3. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of bi- ochemical and pharmacological actions. Eur J Neurol 2001;8:21-9.
4. Rajkumar GN, Conn IG. Botulinum Toxin. A new dimen- sion in the treatment of lower urinary tract dysfunction. Urology 2004;64:2-8.
5. Naumann M, Albanese A, Heinen F et al. Safety and effi- cacy of botulinum toxin type A following long term use. Eur J Neurol 2006;13:35-40.
6. Sloop RR, Cole BA, Escutin RO. Human response to botu- linum toxin injection: type B compared to type A. Neuro- logy 1997;49:189-94.
7. Chapple CR. Which preparation of botulinum toxin A should be used, where should it be injected, and how sho- uld its efficacy be assessed? Eur Urol 2012;61:936-8.
8. Wenzel RG. Pharmacology of botulinum neurotoxin se- rotype A. Am J Health SystPharm 2004;61:5-10.

9. Apostolidis A. Pharmacotherapy for overactive bladder: minimally invasive treatment- botulinum toxins. Exp Opin Pharmacother 2011;12:1029-39.
10. Smith CP, Chancellor MB. The emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004;171:2128-37.
11. Frenkl TL, Rackley RR. Injectable neuromodulatory agents: Botulinum toxin therapy. Urol Clin N Am 2005;32:89-99.
12. Mangera A, Andersson K-E, Apostolidis A et al. Contem- porary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabo- tulinumtoxinA) and Dysport (abobotulinumtoxinA). Eur Urol 2011;60:784-95.
13. Popat R, Apostolidis A, Kalsi V et al. A comparison bet- ween the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984-8.
14. Seth J, Khan MS, Dasgupta P et al. Botulinum toxin- What urologic uses does the data support? Curr Urol Rep 2013;14:227-34.
15. Haylen BT, de Ridder D, Freeman RM et al. An Internati- onal Urogynaecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;19:4-20.
16. Coelho A, Dinis P, Pinto R et al. Distribution of the high- affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 2010;57:884- 90.
17. Liu HT, Chancellor MB, Kuo HC. Urinary growth factor levels are elevated in patients with detrusor oveactivity and decreased in responders to detrusor botulinum toxin-A in- jection. Eur Urol 2009;56:700-6.
18. Apostolidis A, Gasgupta P, Fowler CJ. Proposed mec- hanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644-50.
19. Schurch B, Schmid DM, Stöhrer M. Treatment of neuro- genic incontinence with botulinum toxin A. N Engl J Med 2000;342:665.
20. Anger JT, Weinberg A, Suttorp MJ et al. Outcomes of int- ravesical botulinum toxin for idiopathic overactive blad- der symptoms: a systematic review of the literature. J Urol 2010;183:2258-64.
21. Karsenty G, Denys P, Amarenco G et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neuroge- nic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2007;52:850-8.
22. Apostolidis A, Dasgupta P, Denys P et al. Recommendati- ons on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a Eu- ropean consensus panel report. Eur Urol 2009;55:100-20.
23. Smith CP, Nishuguchi S, O’Leary M et al. Single institution experience in 110 patients with botulinum A toxin injecti- on into bladder or urethra. Urology 2005; 65:37-41.
24. Chancellor MB, Elovic E, Esquenazi A et al. Evidence-ba- sed review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon 2013;67:129-40.
25. Kuo HC. Comparison of effectiveness of detrusor, suburot- helial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 2007;178:1359-63.
26. Dowson C, Khan MS, Dasgupta P et al. Repeat botulinum toxin-A injections for treatment of adult detrusor overac- tivity. Nat Rev Urol 2010;7:661-7.
27. Sahai A, Khan MS, Le Gall N et al. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008;71:455-9.
28. Schulte-Baukloh H, Bigalke H, Miller K et al. Botulinum neurotoxin type A in urology: antibodies as a cuase of the- rapy failure. Int J Urol 2008;15:407-15.
29. Kalsi V, Popat RB, Apostolidis A et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outco- mes observed at a single UK centre. Eur Urol 2006;49:519- 27.
30. Wefer B, Ehlken B, Bremer J et al. Treatment outcomes and resource use of patients with neurogenic detrusor overac- tivity receiving botulinum toxin A (Botox) therapy in Ger- many. World J Urol 2010;28:385-90.
31. Mahfouz W, Karsenty G, Corcos J. Injection of botulinum toxin type A in the urethral sphincter to treat lower uri- nary tract dysfunction: review of indications, techniques and results: 2011 update. Can J Urol 2011;18:5787-95.
32. Kuo HC. Therapeutic outcome and quality of life betwe- en urethral and detrusor botulinum toxin treatment for patients with spinal cord lesions and detrusor sphincter dyssynergia. Int J Clin Pract 2013;67:1044-9.
33. Safari S, Jamali S, Habibollahi P et al. Intravesical injec- tions of botulinum toxin type A for management of neu- ropathic bladder: a comparison of two methods. Urology 2010;76:225-30.
34. Chen CY, Liao CH, Kuo HC. Therapeutic effects of detru- sor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia. Spinal Cord 2011;49:659-64.
35. Kuo HC. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn 2008;27:793-6.
36. Dykstra DD, Sidi AA. Treatment of detrusor sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990;71:24-26.
37. Higgins JR, Gosling JA. Studies of the structure and int- rinsic innervation of the normal human prostate. Prostate 1989;2:5-16.
38. Gkonos PJ, Krongard A, Roos BA. Neuroendocrine pepti- des in the prostate. Urol Res 1995;23:81-7.
39. Chuang YC, Huang CC, Kang HY et al. Novel action of botulinum toxin on the stroma and epithelial components of the prostate gland. J Urol 2006;175:1158-63.
40. Kuo HC, Liu HT. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 2009;43:206-11.
41. Maria G, Brisinda G, Civello IM et al. Relief by botuli- num toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259–65.
42. Marberger M, Chartier-Kastler E, Egerdie B et al. A ran- domized double-blind placebo-controlled phase II dose- ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol 2013;6:496-503.
43. Maria G, Brisinda G, Civello IM et al. Relief by botuli- num toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomised, placebo-controlled study. Urology 2003;62:259-65.
44. Silva J, Silva C, Saraiva L et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presen- ting with refractory urinary retention and benign prostatic enlargement: Effect on prostate volume and micturition resumption. Eur Urol 2008;53:153-9.
45. Crawford ED, Hirst K, Kusek JW et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II ran- domised clinical trial. J Urol 2011;186:965-70.
46. Kuo HC. Prostate botulinum A toxin injection- an alter- native treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005;65:670-4.
47. Chuang YC, Chiang P, Yoshimura N, De Miguel F, Chan- cellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperpla- sia. BJU Int 2006;98:1033-7.
48. Chung YC, Chiang PH, Huang CC et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005;66:775-9.
49. Silva J, Pinto R, Cavalho T et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 2011;107:1950-4.
50. Bouchelouche K, Nording J. Recent developments in the management of interstitial cystitis. Curr Opin Urol 2003;13:309-13.
51. Teichman JM, Moldwin R. The role of the bladder surface in interstitial cystitis/painful bladder syndrome. Can J Urol 2007;14:3599-607.
52. Whitmore KE. Self-care regimens for patients with inters- titial cystitis. Urol Clin North Am 1994;21:121–130.
53. Parsons CL. Interstitial cystitis: successful manage- ment by increasing urinary voiding intervals. Urology 1991;37:207–212.
54. Rothrock NE, Lutgendorf SK, Kreder KJ, Ratliff T, Zim- merman B. Stress and symptoms in patients with interstiti- al cystitis: a life stress model. Urology 2001;57:422-7.
55. Hertle L, van Ophoven A. Long-term results of amitriptyli- ne treatment for interstitial cystitis. Aktuelle Urol 2010;41 Suppl 1:S61-5.
56. Sairanen J, Tammela TL, Leppilahti M et al. Cyclosporine a and pentosan polysulfate sodium for the treatment of in- terstitial cystitis: a randomized comparative study J Urol 2005;174:2235-8.
57. Peters KM, Diokno AC, Steinert BW, Gonzalez JA. The ef- ficacy of intravesical bacillus Calmette-Guerin in the tre- atment of interstitial cystitis: long-term followup. J Urol 1998;159:1483-6.
58. Lazzeri M, Beneforti P, Spinelli M et al. Intravesical resinife- ratoxin for the treatment of hypersensitive disorder: a ran- domized placebo controlled study. J Urol 2000;164:676-9.
59. Pinto R, Lopes T, Silva J et al. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refrac- tory bladder pain syndrome/interstitial cystitis. J Urol 2013;189:548-56.
60. Kuo HC. Repeated intravesical onabotulinumtoxin A injections are effective in treatment of refractory inters- titial cystitis/painful bladder syndrome. Int J Clin Pract 2013;67:427-34.
61. Abbott JA, Jarvis SK, Lyons SD et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a ran- domized controlled trial. Obstet Gynecol 2004:104:922-5.
62. El-Khawand D, Wehbe S, Whitmore K. Botulinum to- xin for conditions of the female pelvis. Int Urogynaecol J 2013;24:1073-81.
63. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginusmus. Obstet Gynecol 2004;104:922-5.
64. Bertolasi L, Frasson E, Cappelletti JY et al. Botulinum neu- rotoxin type A injections for vaginusmus secondary to vul- var vastibulitis syndrome. Obstet Gynecol 2009;114:1008- 16.
65. Serefoglu EC, Silay MS. Botulinum toxin-A injection may be beneficial in the treatment of lifelong premature ejacu- lation. Med Hypotheses 2010;74:83–4.
66. Serefoglu EC, Hawley WR, Lasker GF et al. Effect of botulinum-A toxin injection into bulbospongiosus muscle on ejaculation latency in male rats. J Sex Med 2014;11:1657-63.
67. http://clinicaltrials.gov/show/NCT01917006
68. Berger RE, Ciol MA, Rothman I, Turner JA. Pelvic ten- derness is not limited to the prostate in chronic prosta- titis/chronic pelvic pain syndrome (CPPS) type IIIA and IIIB:comparison of men with and without CP/CPPS. BMC Urol 2007;7:7-17.
69. Hetrick DC, Ciol MA, Rothman I et al. Musculoskeletal dysfunction in men with chronic pelvic pain syndrome type III: a case–control study. J Urol 2003;170:828–31.
70. FitzGerald MP, Anderson RU, Potts J et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndro- mes. J Urol 2009;182:570–80.
71. Anderson RU, Wise D, Sawyer T, Chan C. Integration of myofascial trigger point release and paradoxical relaxation training treatment of chronic pelvic pain in men. J Urol 2005;174:155–60.
72. Yuan RY, Sheu JJ, Yu JM et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009;28:72:1473–8.
73. Zermann D, Ishigooka M, Schubert J, Schmidt RA. Perisp- hincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol 2000;38:393–9.
74. Bschleipfer T, Wagenlehner FM, Weidner W. Intrapros- tatic botulinum toxin A injection in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Urologe A 2007;46:1030–2.